- Home
- MTNB vs NEUP Comparison
MTNB vs NEUP Comparison
Compare MTNB & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- NEUP
- Stock Information
- Founded
- MTNB 2013
- NEUP 1996
- Country
- MTNB United States
- NEUP United States
- Employees
- MTNB N/A
- NEUP N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- MTNB Health Care
- NEUP
- Exchange
- MTNB Nasdaq
- NEUP Nasdaq
- Market Cap
- MTNB 10.8M
- NEUP 12.7M
- IPO Year
- MTNB N/A
- NEUP N/A
- Fundamental
- Price
- MTNB $1.88
- NEUP $19.25
- Analyst Decision
- MTNB Hold
- NEUP Strong Buy
- Analyst Count
- MTNB 1
- NEUP 2
- Target Price
- MTNB N/A
- NEUP $28.00
- AVG Volume (30 Days)
- MTNB 57.2K
- NEUP 93.5K
- Earning Date
- MTNB 11-12-2025
- NEUP 11-15-2025
- Dividend Yield
- MTNB N/A
- NEUP N/A
- EPS Growth
- MTNB N/A
- NEUP N/A
- EPS
- MTNB N/A
- NEUP N/A
- Revenue
- MTNB N/A
- NEUP $15,649,448.00
- Revenue This Year
- MTNB N/A
- NEUP N/A
- Revenue Next Year
- MTNB N/A
- NEUP N/A
- P/E Ratio
- MTNB N/A
- NEUP N/A
- Revenue Growth
- MTNB N/A
- NEUP N/A
- 52 Week Low
- MTNB $0.47
- NEUP $2.90
- 52 Week High
- MTNB $4.25
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- MTNB 53.90
- NEUP 80.30
- Support Level
- MTNB $1.83
- NEUP $10.47
- Resistance Level
- MTNB $1.97
- NEUP $13.28
- Average True Range (ATR)
- MTNB 0.13
- NEUP 1.93
- MACD
- MTNB -0.01
- NEUP 0.87
- Stochastic Oscillator
- MTNB 46.94
- NEUP 88.32
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.